%PDF-1.4
%
74 0 obj
<>
endobj
76 0 obj
<>stream
2009-09-17T15:58:07Z
QuarkXPress(tm) 6.5
2013-10-11T13:34:13-07:00
2013-10-11T13:34:13-07:00
QuarkXPress(tm) 6.5
application/pdf
Layout 1
%%DocumentProcessColors: Black
%%EndComments
uuid:2e2ae21d-1dd2-11b2-0a00-6109273dd000
uuid:2e2ae221-1dd2-11b2-0a00-15f600000000
endstream
endobj
16 0 obj
<>]>>
endobj
70 0 obj
<>
endobj
63 0 obj
<>
endobj
71 0 obj
<>
endobj
72 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
73 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
15 0 obj
<>stream
/GS0 gs
1 g
0 792 0 0 re
f
q
/GS1 gs
0 0 0 0 k
318 745 234 10 re
f
Q
/GS1 gs
q
BT
/F18 1 Tf
8 0 0 8 348.6847 749.5293 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
(Impact of Renal Drug Dosing Service in Chronic Kidney Disease)Tj
ET
0 0 0 0 k
167 17.75 385 13 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10 0 0 10 268.0323 23.9116 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(The Annals of Phar)-25(macotherapy )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
5 0 0 5 401.1573 25.4116 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10 0 0 10 414.3384 23.9116 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(2009 October)110(, V)110(olume 43 )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
5 0 0 5 519.569 25.4116 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
10 0 0 10 532.75 23.9116 Tm
0 0 0 1 k
-0.024 Tc
(1605)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10 0 0 10 60 23.6616 Tm
0 0 0 1 k
-0.025 Tc
(theannals.com)Tj
ET
0 0 0 0 k
60 128.2089 492 609.791 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
8 0 0 8 60 732.5292 Tm
0 0 0 1 k
-0.011 Tc
0.011 Tw
[(37.)-489(Manley HJ, Carroll CA. The clinical and economic impact of phar)-25(ma)-1(-)]TJ
1.6875 -1.25625 TD
-0.04 Tc
0.013 Tw
[(ceutical care in end-stage renal disease patients. Semin Dial 2002;15:45)-25(-9.)]TJ
-1.6875 -1.375 TD
-0.025 Tc
0.006 Tw
[(38.)-475(Kaplan B, Shimp LA, Mason NA, Ascione FJ. Chronic hemodialysis pa-)]TJ
1.6875 -1.25 TD
-0.022 Tc
0.021 Tw
(tients. Part II: reducing drug-related problems through application of the)Tj
T*
-0.035 Tc
0.013 Tw
[(focused drug therapy review program. Ann Phar)-25(macother 1994;28:320)-75(-)-125(4.)]TJ
-1.6875 -1.375 TD
-0.02 Tc
0.02 Tw
[(39.)-480(W)80(ang HY)130(, Chan AL, Chen MT)75(, Liao CH. Ef)20(fect of phar)-25(maceutical care)]TJ
1.6875 -1.25 TD
-0.025 Tc
0.005 Tw
[(intervention by clinical phar)-25(macists in renal transplant clinics. T)35(ransplant)]TJ
T*
0.013 Tw
[(Proc 2008;40:2319)-25(-)-25(23.)]TJ
-1.6875 -1.375 TD
-0.002 Tc
0.002 Tw
[(40.)-498(Grabe DW)90(, Low CL, Bailie GR, Eisele G. Evaluation of drug-related)]TJ
1.6875 -1.25 TD
-0.018 Tc
0.018 Tw
(problems in an outpatient hemodialysis unit and the impact of a clinical)Tj
T*
-0.025 Tc
0.013 Tw
[(phar)-25(macist. Clin Nephrol 1997;47:1)35(17-)-25(21.)]TJ
-1.6875 -1.375 TD
0.025 Tw
[(41.)-475(Mof)20(fett BS, Mott AR, Nelson DP)110(, Gurwitch KD. Medication dosing and)]TJ
1.6875 -1.25 TD
-0.007 Tc
0.006 Tw
[(renal insuf)20(ficiency in a pediatric cardiac intensive care unit: impact of)]TJ
T*
-0.025 Tc
0.013 Tw
[(phar)-25(macist consultation. Pediatr Cardiol 2008;29:744)-75(-)-25(8.)]TJ
-1.6875 -1.375 TD
0 Tc
0.059 Tw
[(42.)-500(Leape LL, Cullen DJ, Clapp MD, et al. Phar)-25(macist participation on)]TJ
1.6875 -1.25 TD
-0.037 Tc
0.022 Tw
(physician rounds and adverse drug events in the intensive care unit. JAMA)Tj
T*
-0.025 Tc
0 Tw
(1999;282:267-70.)Tj
-1.6875 -1.375 TD
-0.024 Tc
0.024 Tw
[(43.)-476(Gandhi PJ, Smith BS, T)70(ataronis GR, Maas B. Impact of a phar)-25(macist on)]TJ
1.6875 -1.25 TD
0 Tc
0.001 Tw
[(drug costs in a coronary care unit. Am J Health Syst Phar)-25(m 2001;58:)]TJ
T*
-0.025 Tc
0 Tw
(497-503.)Tj
ET
1 w
0 0 0 1 K
114 513.979 m
240 513.979 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
9 0 0 9 60 489.4793 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
(Impacto de un Programa de Dosificaci\227n en el Ajuste de Dosis en)Tj
0 -1.22222 TD
[(Pacientes Hospitalizados con Enfer)-25(medad Cr\227nica del Ri\226\227n en)]TJ
T*
0 Tw
(Malasia )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
8 0 0 8 60 453.4793 Tm
0 0 0 1 k
-0.0251 Tc
(Y)Tj
0.93433 0 Td
-0.025 Tc
0.013 Tw
(Hassan, R\325J Al-Ramahi, NA Aziz, y R Ghazali)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8 0 0 8 60 437.4793 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(Ann Phar)-25(macother)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
8 0 0 8 120.0947 437.4793 Tm
0 0 0 1 k
-0.025 Tc
[(2009;43:1598)-25(-)-75(605.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
7.5 0 0 7.5 60 411.9793 Tm
0 0 0 1 k
-0.025 Tc
(EXTRACT)Tj
4.41532 0 TD
0 Tc
(O)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6 0 0 6 60 398.4793 Tm
0 0 0 1 k
-0.024 Tc
(TRASFONDO:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
8.5 0 0 8.5 100.1778 398.4793 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
(La selecci\227n y dosificaci\227n adecuadas de medicamentos)Tj
-4.7268 -1.11765 TD
(para pacientes con enfer)Tj
9.14987 0.00001 TD
(medad cr\227nica del ri\226\227n (CKD) es importante)Tj
-9.14987 -1.11765 TD
(para evitar efectos no deseados y asegurar resultados \227ptimos en los)Tj
0 -1.11764 TD
0 Tw
(pacientes.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6 0 0 6 60 357.4793 Tm
0 0 0 1 k
-0.024 Tc
(OBJETIV)Tj
4.19462 0 TD
-0.022 Tc
(O:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
8.5 0 0 8.5 93.55 357.4793 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
(Evaluar el \222ndice de dosificaci\227n inapropiada en pacientes con)Tj
-3.94706 -1.11764 TD
-0.04 Tc
(CKD en una unidad de nefrolog\222a y evaluar el impacto de un far)Tj
23.406 0 TD
0 Tw
(mac\216utico)Tj
-23.406 -1.11765 TD
-0.025 Tc
0.012 Tw
(en el ajuste en dosis de medicamentos, eventos de reacciones adversas)Tj
T*
((ADEs) y costo en medicamentos, al realizar rondas con el equipo de)Tj
T*
0 Tw
(m\216dicos.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6 0 0 6 60 306.9793 Tm
0 0 0 1 k
-0.0231 Tc
(MET)Tj
2.1828 0 TD
-0.024 Tc
(ODOLOG\352A:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
8.5 0 0 8.5 109.4286 306.9793 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
(El estudio consisti\227 de una fase de pre-intervenci\227n)Tj
-5.81513 -1.11764 TD
((grupo control) y una fase de intervenci\227n. Dos muestras aleatorias de)Tj
0 -1.11765 TD
-0.04 Tc
(300 pacientes con una depuraci\227n estimada de creatinina )Tj
/F19 1 Tf
20.84918 0.00001 TD
0 Tc
Tj
/F4 1 Tf
0.50882 0.00001 TD
-0.04 Tc
(50 mL/minutos)Tj
-21.358 -1.11766 TD
(fueron incluidos. Durante la fase de pre-intervenci\227n se realiz\227 observaci\227n)Tj
0 -1.11764 TD
-0.025 Tc
(prospectiva durante un per\222odo de 4 meses. Durante la fase de inter)Tj
25.33865 0.00001 TD
0 Tc
(-)Tj
-25.33865 -1.11766 TD
-0.025 Tc
[(venci\227n, un far)-25(mac\216utico cl\222nico realiz\227 rondas junto al equipo de l)15(a)]TJ
0 -1.11764 TD
-0.04 Tc
(unidad de nefrolog\222a y recomend\227 ajustes en dosis cuando era necesario.)Tj
T*
-0.025 Tc
(Se prepar\227 un manual de bolsillo para realizar las recomendaciones,)Tj
0 -1.11765 TD
(utilizando referencias actualizadas y confiables.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6 0 0 6 60 218.4793 Tm
0 0 0 1 k
-0.024 Tc
[(RESUL)91(T)75(ADOS:)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
8.5 0 0 8.5 102.0434 218.4793 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
(Durante la fase de pre-intervenci\227n 607 (21.6%) \227rdenes de)Tj
-4.94628 -1.11764 TD
(un total de 2814 requer\222an ajuste en dosis o cambio en medicamento,)Tj
0 -1.11765 TD
-0.04 Tc
(basado en la funci\227n renal del paciente. De \216stas, 322 (53%) no cumplieron)Tj
0 -1.11764 TD
-0.025 Tc
(con las gu\222as de dosificaci\227n para pacientes con CKD que recomiendan)Tj
T*
(las referencias. Durante la fase de intervenci\227n 640 (21.5%) \227rdenes de)Tj
0 -1.11765 TD
[(un total de 2981 requer\222an ajuste en dosis. El far)-25(mac\216utico realiz\227 388)]TJ
0 -1.11764 TD
(recomendaciones relacionadas con ajuste en dosis, de las cuales 212)Tj
T*
((54.6%) fueron aceptadas por los m\216dicos. El incumplimiento de los)Tj
0 -1.11765 TD
(m\216dicos con las gu\222as de dosificaci\227n disminuy\227 a 176 \(27.5%, p <)Tj
0 -1.11764 TD
(0.001\) \227rdenes de los medicamentos estudiados. Durante la fase de pre-)Tj
30.35294 70.49507 TD
-0.0251 Tc
(i)Tj
0.25292 -0.00001 TD
-0.025 Tc
(ntervenci\227n 64 (21.3%) pacientes tuvieron sospecha de un ADE para)Tj
-0.25292 -1.11764 TD
(un total de 73 eventos. En el grupo de las intervenciones este n\234mero)Tj
T*
(fue significativamente menor \(49 eventos en 48 [16.0%] pacientes, p <)Tj
0 -1.11765 TD
(0.05\). Las intervenciones resultaron en una econom\222a de $2250.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6 0 0 6 318 691.1874 Tm
0 0 0 1 k
-0.024 Tc
(CONCLUSIONES:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
8.5 0 0 8.5 368.0652 691.1874 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
(Un programa de dosificaci\227n de medicamentos para)Tj
-5.89002 -1.11764 TD
(pacientes hospitalizados con CKD puede aumentar la proporci\227n de)Tj
0 -1.11765 TD
(ajuste en dosis de medicamentos al tomar en consideraci\227n la funci\227n)Tj
0 -1.11764 TD
-0.0251 Tc
(r)Tj
0.30791 -0.00001 TD
-0.025 Tc
(enal. Esto puede resultar en econom\222a en costos de medicamentos y)Tj
-0.30791 -1.11764 TD
(puede prevenir ADEs.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
8 0 0 8 443.2344 636.6873 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(T)35(raducido por Astrid J Garc\222a-)-50(Ortiz)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
9 0 0 9 318 610.6874 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
[(Impact des Interventions d\325un Phar)-25(macien Clinicien aupr\217s de)]TJ
0 -1.22222 TD
[(Patients Souf)20(frant d\325Insuf)20(fisance R\216nale Chronique Hospitalis\216s)]TJ
T*
(dans une Unit\216 de N\216phrologie en Malaisie )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
8 0 0 8 318 574.6873 Tm
0 0 0 1 k
-0.0251 Tc
(Y)Tj
0.93432 0 Td
-0.025 Tc
0.013 Tw
(Hassan, R\325J Al-Ramahi, NA Aziz, et R Ghazali)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8 0 0 8 318 558.6874 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(Ann Phar)-25(macother)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
8 0 0 8 378.0947 558.6874 Tm
0 0 0 1 k
-0.025 Tc
[(2009;43:1598)-25(-)-75(605.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
7.5 0 0 7.5 318 533.1874 Tm
0 0 0 1 k
-0.025 Tc
(R\203SUM\203)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6 0 0 6 318 519.6874 Tm
0 0 0 1 k
-0.0239 Tc
(I)Tj
0.36415 -0.00001 TD
-0.024 Tc
(NTRODUCTION:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
8.5 0 0 8.5 368.0593 519.6874 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
(Le choix et la posologie d\325un m\216dicament chez les)Tj
-5.88933 -1.11764 TD
[(patients atteints d\325insuf)20(fisance r\216nale chronique sont particuli\217rement)]TJ
0 -1.11765 TD
[(importants pour optimiser les ef)20(fets th\216rapeutiques tout en minimisant)]TJ
0 -1.11764 TD
[(les ef)20(fets ind\216sirables.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6 0 0 6 318 478.6874 Tm
0 0 0 1 k
-0.024 Tc
(OBJECTIF:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
8.5 0 0 8.5 350.6682 478.6874 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
(Estimer la fr\216quence \210 laquelle des dosages inad\216quats sont)Tj
-3.84332 -1.11764 TD
[(prescrits aux patients souf)20(frant d\325insuf)20(fisance r\216nale chronique dans une)]TJ
0 -1.11765 TD
(unit\216 de soins de n\216phrologie et \216valuer l\325impact de la pr\216sence d\325un)Tj
0 -1.11764 TD
[(phar)-25(macien au sein de l\325\216quipe soignante sur l\325ajustement des doses, les)]TJ
T*
0 Tw
(ef)Tj
0.70659 0 TD
0.012 Tw
(fets secondaires, et les co\236ts.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6 0 0 6 318 428.1874 Tm
0 0 0 1 k
-0.024 Tc
0.013 Tw
[(DEVIS EXP\203RIMENT)76(AL:)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
8.5 0 0 8.5 387.6205 428.1874 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
(Il s\325agit d\325une \216tude comparant la situation durant)Tj
-8.19065 -1.11765 TD
[(l\325intervention du phar)-25(macien \210 celle pr\216c\216dant son intervention. Deux)]TJ
0 -1.11764 TD
(\216chantillons de 300 patients ayant une clairance \210 la cr\216atinine estim\216e \210)Tj
/F19 1 Tf
0 -1.11765 TD
0 Tc
Tj
/F4 1 Tf
0.52383 0 Td
-0.025 Tc
(50 mL/minute ont \216t\216 inclus. Au cours de la phase d\325intervention, un)Tj
-0.52383 -1.11765 TD
[(phar)-25(macien clinicien accompagnait l\325\216quipe m\216dicale dans sa tour)-25(n\216e)]TJ
0 -1.11764 TD
(des patients hospitalis\216s \210 l\325unit\216 de soins de n\216phrologie et donnait des)Tj
T*
(recommandations, lorsque n\216cessaire, quant \210 l\325ajustement des doses de)Tj
0 -1.11765 TD
(m\216dicaments. Une compilation des sources de r\216f\216rence les plus)Tj
0 -1.11764 TD
[(r\216centes \216tait \210 la disposition du phar)-25(macien pour ses interventions.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6 0 0 6 318 339.6874 Tm
0 0 0 1 k
-0.024 Tc
(R\203SUL)Tj
3.11865 0 TD
0 Tc
(T)Tj
0.56678 0 TD
(A)Tj
0.62173 0 TD
-0.024 Tc
(TS:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
8.5 0 0 8.5 354.7457 339.6874 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
(Dans le groupe pr\216-intervention, un ajustement de la dose ou)Tj
-4.32302 -1.11765 TD
(encore l\325arr\220t complet du m\216dicament \210 cause de la fonction r\216nale a \216t\216)Tj
0 -1.11764 TD
(n\216cessaire pour 607 des 2814 (21.6%) prescriptions. Dans 322 (53.0%))Tj
0 -1.11765 TD
(cas, la prescription \216tait en contradiction avec les guides th\216rapeutiques)Tj
0 -1.11764 TD
-0.04 Tc
(existants. Dans le groupe ayant b\216n\216fici\216 de l\325intervention du phar)Tj
24.00149 0.00001 TD
0 Tw
(macien,)Tj
-24.00149 -1.11766 TD
-0.025 Tc
0.012 Tw
(l\325ajustement a \216t\216 n\216cessaire pour 640 des 2981 (21.5%) prescriptions.)Tj
0 -1.11764 TD
(Le phar)Tj
2.94369 0.00001 TD
(macien ef)Tj
3.68128 0.00001 TD
(fectua 388 recommandations concer)Tj
13.70221 0.00001 TD
(nant la dose et 212)Tj
-20.32719 -1.11767 TD
((54.6%) furent accept\216es par le m\216decin. La non observance par les)Tj
0 -1.11764 TD
-0.04 Tc
(cliniciens des guides th\216rapeutiques n\325a \216t\216 constat\216 que dans 176 (27.5%))Tj
T*
-0.025 Tc
(cas, une diminution significative par rapport au groupe pr\216-intervention)Tj
0 -1.11765 TD
((p < 0.001). Dans le groupe pr\216-intervention, 64 (21.3%) des patients a)Tj
0 -1.11764 TD
0 Tw
(souf)Tj
1.60166 0.00001 TD
0.012 Tw
[(fert d\325un ef)20(fet secondaire, pour un total de 73 \216v\216nements. Dans le)]TJ
-1.60166 -1.11765 TD
(groupe avec intervention, ce nombre \216tait significativement plus bas: 49)Tj
T*
[(\216v\216nements chez 48 (16.0%) patients (p < 0.05). L)90(\325intervention du)]TJ
0 -1.11764 TD
[(phar)-25(macien s\325est sold\216 par des \216conomies se chif)20(frant, en ter)-25(mes de)]TJ
T*
(m\216dicaments seulement, \210 2250 USD. )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6 0 0 6 318 184.6873 Tm
0 0 0 1 k
-0.024 Tc
(CONCLUSIONS:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
8.5 0 0 8.5 364.2133 184.6873 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
[(La pr\216sence d\325un phar)-25(macien dans l\325\216quipe de)]TJ
-5.43686 -1.11764 TD
[(n\216phrologie per)-25(met de mieux ajuster les doses de m\216dicaments chez les)]TJ
T*
(patients souf)Tj
4.74924 0.00001 TD
(frant d\325insuf)Tj
4.63695 0.00001 TD
(fisance r\216nale chronique, et ainsi r\216duire le)Tj
-9.3862 -1.11767 TD
[(nombre d\325ef)20(fets secondaires et les co\236ts. )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
8 0 0 8 462.5398 139.6873 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(T)35(raduit par Suzanne Laplante)]TJ
ET
Q
endstream
endobj
20 0 obj
<>
endobj
24 0 obj
<>
endobj
60 0 obj
<>
endobj
62 0 obj
<>
endobj
28 0 obj
<>
endobj
36 0 obj
<>
endobj
33 0 obj
<>
endobj
35 0 obj
<>
endobj
34 0 obj
<>stream
MUWCUH+Times-Roman @